Clinical Core

马萨诸塞州阿尔茨海默病研究中心：临床核心 马萨诸塞州阿尔茨海默病研究中心(MADRC)的临床核心与 MADRC作为一个整体：支持对阿尔茨海默病的病因、机制和治疗的研究 和阿尔茨海默病相关疾病(AD/ADRD)，最终目标是治愈甚至预防。为了方便 在这些领域的研究，我们正在调整我们的研究队列，研究队列中来自不同种族和 种族背景，以实现更多数量和更多样化的受损参与者，并追求 普遍的深度临床、影像和分子表型鉴定。这将使该队列能够充当我们的 中心的“实验室”，以了解疾病的异质性，并加快AD/ADRD的治疗。至 要实现这些目标，我们有三套目标： 第一组(目标1-4)旨在调集资源，重点是开发和维护一口井-- 特征研究队列，以确保我们有足够数量的MCI和痴呆症 AD/ADRD。我们支持在AD/ADRD范围内招募受损人员，并将提交年度UD 对NACC进行评估，并对我们的参与者进行遗传、体液和成像生物标记物采样，外加获得 同意脑部捐献。我们还维护了附属MGH记忆部的患者数据库 诊所(记忆障碍、FTD和DLB)推荐更多的“准备好研究”的参与者(研究 队列加临床患者)，用于广泛的地方和国家观察研究和临床试验。 第二组(目标5-6)旨在制定新的战略，重点是实现普遍深入 我们研究队列的表型和早期临床新仪器的开发和验证 用于临床环境和临床试验的检测。我们将使用我们的研究队列，具有深入的临床， 成像和分子表型，作为我们中心的实验室，测试关于临床和 AD/ADRD的生物学差异和共性，以及开发和验证可能 加快靶点发现和临床试验进程。我们将继续将我们的数据和发现与 其他ADRC和更广泛的科学界进行验证和实施。 最后一组(目标7-8)旨在建设未来，重点培养未来一代的临床医生- 科学家和促进痴呆症预防工作和个人的研究机会 社区，特别是那些没有得到充分服务的少数群体。这些努力将在密切合作中完成 与REC和ORE Core合作。我们的目标是让所有利益相关者--患者、护理人员、临床医生和研究人员--参与进来 -作为直接合作伙伴，加速治愈AD/ADRD。

Massachusetts Alzheimer’s Disease Research Center: Clinical Core The Clinical Core of the Massachusetts Alzheimer’s Disease Research Center (MADRC) parallels that of the MADRC as a whole: to support research into the causes, mechanisms and treatment of Alzheimer’s disease and Alzheimer-related disorders (AD/ADRD), with the eventual goal of cure and even prevention. To facilitate research in these areas, we are revamping our Research Cohort of men and women from diverse ethnic and racial backgrounds to achieve a larger number and greater diversity of impaired participants and pursue universal deep clinical, imaging, and molecular phenotyping. This will enable the Cohort to serve as our Center’s “laboratory” to understand disease heterogeneity and accelerate treatments for AD/ADRD. To accomplish these goals, we have three sets of Aims: The first group (Aims 1-4), intended to marshal resources, focuses on developing and maintaining a well- characterized Research Cohort to ensure that we have sufficient numbers of MCI and dementia across AD/ADRD. We bolster our recruiting of impaired individuals across AD/ADRD, and will submit annual UDS evaluations to NACC and sample our participants for genetic, fluid, and imaging biomarkers, plus obtain consent for brain donation. We also maintain a database of patients from the affiliated MGH Memory Division clinics (Memory Disorders, FTD and DLB) to refer a larger pool of “research ready” participants (Research Cohort plus Clinic Patients) to a wide range of local and national observational studies and clinical trials. The second group (Aims 5-6), intended to develop new strategies, focuses on achieving universal deep phenotyping of our Research Cohort and developing and validating novel clinical instruments for early detection for use in clinical settings and clinical trials. We will use our Research Cohort, with deep clinical, imaging and molecular phenotyping, as our Center’s “laboratory” to test hypotheses about clinical and biological differences and commonalities in AD/ADRD and to develop and validate biomarkers that may expedite target discovery and clinical trial process. We will continue to share our data and discoveries with other ADRCs and the broader scientific community for validation and implementation. The final group (Aims 7-8), intended to build the future, focuses on training future generations clinician- scientists and on promoting dementia prevention efforts and research opportunities to individuals in the community, particularly those from underserved minorities. These efforts will be done in close collaboration with REC and ORE Core. We aim to engage all stakeholders - patients, caregivers, clinicians and researchers - as direct partners to accelerate toward a cure for AD/ADRD.